Boston Scientific has struck a $600 million deal to acquire Augmenix for a device that reduces the side effects of prostate cancer radiotherapy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,